Pia Osterlund
Department of Oncology
Helsinki University Central Hospital
P.O. Box 180
HUS Helsinki 00029
Finland
Name/email consistency: high
- Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy. Österlund, P., Soveri, L.M., Isoniemi, H., Poussa, T., Alanko, T., Bono, P. Br. J. Cancer (2011)
- Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer: a randomised study. Osterlund, P., Ruotsalainen, T., Korpela, R., Saxelin, M., Ollus, A., Valta, P., Kouri, M., Elomaa, I., Joensuu, H. Br. J. Cancer (2007)
- Lactose intolerance associated with adjuvant 5-fluorouracil-based chemotherapy for colorectal cancer. Osterlund, P., Ruotsalainen, T., Peuhkuri, K., Korpela, R., Ollus, A., Ikonen, M., Joensuu, H., Elomaa, I. Clin. Gastroenterol. Hepatol. (2004)
- Raltitrexed treatment promotes systemic inflammatory reaction in patients with colorectal carcinoma. Osterlund, P., Orpana, A., Elomaa, I., Repo, H., Joensuu, H. Br. J. Cancer (2002)
- A phase I study of raltitrexed (Tomudex) combined with carmofur in metastatic colorectal cancer. Osterlund, P., Elomaa, I., Virkkunen, P., Joensuu, H. Oncology (2001)